Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

被引:23
|
作者
Jensen, Agnete Witness Praest [1 ]
Simoes, Ana Micaela Carnaz [1 ]
Straten, Per Thor [1 ,2 ]
Olofsson, Gitte Holmen [1 ]
机构
[1] Univ Hosp, Natl Ctr Canc Immune Therapy DK CCIT, Dept Oncol, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, DK-2200 Copenhagen, Denmark
关键词
β -2 adrenergic receptor; 2AR; adrenergic receptor; exercise; physical activity; cancer; T cell; NK cell; -blocker; RECEPTOR-MEDIATED HUMAN; PHYSICAL-ACTIVITY; BREAST-CANCER; CHRONIC STRESS; MOLECULAR-MECHANISMS; IMMUNE FUNCTION; TUMOR-GROWTH; T-CELLS; IN-VIVO; EXERCISE;
D O I
10.3390/cancers13030394
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Exercise is associated with many aspects of a healthy lifestyle. Among these, exercise leads to the secretion of adrenaline and noradrenaline, which mobilize cells of the immune system, a process which is suggested to possess therapeutic value in cancer therapy, alone or in combination with immunotherapy. Strikingly, administration of beta-blockers-which block the effect of adrenaline/noradrenaline-are also suggested to be useful in cancer therapy alone or in combination with immunotherapy. Herein we discuss the question of whether exercise and the administration of beta-blockers could potentially be useful in cancer therapy. The incidence of cancer is increasing worldwide, which is to a large extent related to the population's increasing lifespan. However, lifestyle changes in the Western world are causative as well. Exercise is intrinsically associated with what one could call a "healthy life", and physical activity is associated with a lower risk of various types of cancer. Mouse models of exercise have shown therapeutic efficacy across numerous cancer models, at least in part due to the secretion of adrenaline, which mobilizes cells of the immune system, i.e., cytotoxic T and natural killer (NK) cells, through signaling of the beta-2 adrenergic receptor (beta 2AR). Clinical trials aiming to investigate the clinical value of exercise are ongoing. Strikingly, however, the use of beta-blockers-antagonists of the very same signaling pathway-also shows signs of clinical potential in cancer therapy. Cancer cells also express beta-adrenergic receptors (beta ARs) and signaling of the receptor is oncogenic. Moreover, there are data to suggest that beta 2AR signaling in T cells renders the cell functionally suppressed. In this paper, we discuss these seemingly opposing mechanisms of cancer therapy-exercise, which leads to increased beta 2AR signaling, and beta-blocker treatment, which antagonizes that same signaling-and suggest potential mechanisms and possibilities for their combination.
引用
收藏
页码:1 / 16
页数:15
相关论文
共 50 条
  • [1] Ferroptosis: friend or foe in cancer immunotherapy?
    Demuynck, Robin
    Efimova, Iuliia
    Catanzaro, Elena
    Krysko, Dmitri, V
    [J]. ONCOIMMUNOLOGY, 2023, 12 (01):
  • [2] β-adrenergic signaling in chronic heart failure -: Friend or foe?
    Maack, C
    Böhm, M
    [J]. SIGNAL TRANSDUCTION AND CARDIAC HYPERTROPHY, 2003, 7 : 303 - 321
  • [3] Interleukin-21 in cancer immunotherapy Friend or foe?
    Stolfi, Carmine
    Pallone, Francesco
    Macdonald, Thomas T.
    Monteleone, Giovanni
    [J]. ONCOIMMUNOLOGY, 2012, 1 (03) : 351 - 354
  • [4] Thermoablation Friend and foe of immunotherapy
    Radosa, Christoph G.
    Hoffmann, Ralf-Thorsten
    [J]. RADIOLOGE, 2020, 60 (08): : 704 - 710
  • [5] STING signaling in tumorigenesis and cancer therapy: A friend or foe?
    He, Liangmei
    Xiao, Xiaomei
    Yang, Xi
    Zhang, Zixiang
    Wu, Longhuo
    Liu, Zhiping
    [J]. CANCER LETTERS, 2017, 402 : 203 - 212
  • [6] Protein kinase D signaling in cancer: A friend or foe?
    Roy, Adhiraj
    Ye, Jing
    Deng, Fan
    Wang, Qiming Jane
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2017, 1868 (01): : 283 - 294
  • [7] Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
    Song, Jingjing
    Wu, Lihui
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [8] Tumor Temperature: Friend or Foe of Virus-Based Cancer Immunotherapy
    Knapp, Jason P.
    Kakish, Julia E.
    Bridle, Byram W.
    Speicher, David J.
    [J]. BIOMEDICINES, 2022, 10 (08)
  • [9] Androgen Signaling in Prostate Cancer: When a Friend Turns Foe
    Pandey, Swaroop Kumar
    Sabharwal, Usha
    Tripathi, Swati
    Mishra, Anuja
    Yadav, Neha
    Dwivedi-Agnihotri, Hemlata
    [J]. ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2024,
  • [10] Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
    Cong Yan
    Xiao-Xuan Tu
    Wei Wu
    Zhou Tong
    Lu-Lu Liu
    Yi Zheng
    Wei-Qin Jiang
    Peng Zhao
    Wei-Jia Fang
    Hang-Yu Zhang
    [J]. World Journal of Clinical Cases, 2019, (11) : 1253 - 1261